Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis

被引：13

作者：

Leung, Nelson ^{[1
]}

Pittelkow, Mark R. ^{[2
]}

Lee, Christine U. ^{[3
]}

Good, Jonathan A. ^{[4
]}

Hanley, Matthew M. ^{[4
]}

Moyer, Thomas P. ^{[4
]}

机构：

[1] Mayo Clin Rochester, Div Nephrol & Hypertens, Rochester, MN 55902 USA

[2] Mayo Clin Rochester, Dept Dermatol, Rochester, MN USA

[3] Mayo Clin Rochester, Dept Radiol, Rochester, MN USA

[4] Mayo Clin Rochester, Dept Lab Med & Pathol, Rochester, MN USA

来源：

CLINICAL KIDNEY JOURNAL | 2009年 / 2卷 / 03期

关键词：

chelation; deferoxamine; gadolinium;

D O I：

10.1093/ndtplus/sfp042

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

A 65-year-old female with biopsy-confirmed nephrogenic systemic fibrosis (NSF) received a kidney transplantation. Despite good kidney function, her symptoms continued to progress. Deferoxamine was administered intra-muscularly at 500 mg/day and later 1000 mg/day after 1 week with no adverse effects. Urine excretion of gadolinium increased from 6.0 mu g/day to 11.6 mu g/day and subsequently to 13.0 mu g/day with 500 mg/day and 1000 mg/day of deferoxamine, respectively. Serum levels, however, remain unchanged from 1.7 ng/ml to 1.4 ng/ml. Although chelation therapy may have a role in the treatment of NSF, deferoxamine is too weak and a stronger chelator is needed.

引用

页码：309 / 311

页数：3

共 12 条

[1] Treatment With Imatinib Prevents Fibrosis in Different Preclinical Models of Systemic Sclerosis and Induces Regression of Established Fibrosis [J].

Akhmetshina, Alfiva ;

Venalis, Paulius ;

Dees, Clara ;

Busch, Nicole ;

Zwerina, Jochen ;

Schett, Georg ;

Distler, Oliver ;

Distler, Joerg H. W. .

ARTHRITIS AND RHEUMATISM, 2009, 60 (01) :219-224

[2] Imatinib in the Treatment of Nephrogenic Systemic Fibrosis [J].

Chandran, Sindhu ;

Petersen, Jeffrey ;

Jacobs, Charlotte ;

Forentino, David ;

Doeden, Katherine ;

Lafayette, Richard A. .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (01) :129-132

[3] Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure [J].

Grobner, Thomas ;

Prischl, Friedrich C. .

SEMINARS IN DIALYSIS, 2008, 21 (02) :135-139

[4] Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis [J].

High, Whitney A. ;

Ayers, Reed A. ;

Chandler, John ;

Zito, Gary ;

Cowper, Shawn E. .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (01) :21-26

[5] Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis [J].

Joffe, P ;

Thomsen, HS ;

Meusel, M .

ACADEMIC RADIOLOGY, 1998, 5 (07) :491-502

[6] Imatinib mesylate treatment of nephrogenic systemic fibrosis [J].

Kay, Jonathan ;

High, Whitney A. .

ARTHRITIS AND RHEUMATISM, 2008, 58 (08) :2543-2548

[7] Nephrogenic systemic fibrosis: Early recognition and treatment [J].

Knopp, Eleanor A. ;

Cowper, Shawn E. .

SEMINARS IN DIALYSIS, 2008, 21 (02) :123-128

[8] Treatment of nephrogenic systemic fibrosis: Limited options but hope for the future [J].

Linfert, Douglas R. ;

Schell, Jane O. ;

Fine, Derek M. .

SEMINARS IN DIALYSIS, 2008, 21 (02) :155-159

[9] Nephrogenic fibrosing dermopathy - A comprehensive review for the dermatologist [J].

Scheinfeld, Noah .

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2006, 7 (04) :237-247

[10] PHARMACOKINETICS OF GD-DTPA IN PATIENTS WITH CHRONIC-RENAL-FAILURE [J].

SCHUHMANNGIAMPIERI, G ;

KRESTIN, G .

INVESTIGATIVE RADIOLOGY, 1991, 26 (11) :975-979

← 1 2 →